Showing 2471-2480 of 9104 results for "".
Laser Skin Rejuvenation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-skin-rejuvenation/19408/Dr. Amy Derick reviews the latest in lasers for improving skin tone, texture and laxity.How to Choose the Right Filler
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-to-choose-the-right-filler/19411/Dr. Amy Derick reviews key points about injectable fillers, a non-invasive alternative to surgical facelifts.Dr. Chan Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-chan-discusses-experience-with-gemini-laser/19471/“Gemini is an extremely effective non-ablative skin rejuvenation laser. And by combining the 532 KTP lasers with the long pulse 1064 YAG, we can achieve non-ablative skin rejuvenations in terms of reductions of pigmentations, fine lines, pore size and vessel improvement.” & #8212Professor HenryBodyJet Infiltration
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bodyjet_meyer-infiltration/19520/Demonstration of cannula placement in the anterior and posterior thigh.Effector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urImproving Care Options for CTCL
https://practicaldermatology.com/series/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.The Evolving Needs of the Modern Patient
https://practicaldermatology.com/series/c-suite-chats/the-evolving-needs-of-the-modern-patient/39900/Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs.Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-socioeconomic-neighborhood-status-linked-with-hs-severity-plus-more/39881/This episode highlights new data linking neighborhood socioeconomic status to hidradenitis suppurativa severity, as well as a new study of mitochondrial decline in skin cells leading to skin aging and even obesity. Also, a new Atopic Dermatitis Journal Club examines combination therapy with dupilumaWorking up Prurigo Nodularis and Getting to the Source of Itch
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37146/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, discusses how to identify and address the source of itch in prurigo nodularis cases.DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe a